Hydroxyzine for generalised anxiety disorder

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Guaiana, Giuseppe ^a   Barbui, C ^b   Churchill, R ^b   Cipriani, A ^b   McGuire, H F ^b  

^a Clinica Psichiatrica Cantonale   (Switzerland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HYDROXYZINE; MILNACIPRAN; MIRTAZAPINE; MOCLOBEMIDE; NEUROLEPTIC AGENT; PAROXETINE; PHENELZINE; PLACEBO; REBOXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; VENLAFAXINE;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA ANALYSIS; DATA EXTRACTION; DRUG EFFICACY; DRUG TOLERABILITY; GENERALIZED ANXIETY DISORDER; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; QUALITY CONTROL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; SENSITIVITY ANALYSIS;

EID: 44949222551     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006815     Document Type: Review

References (31)

1. Altman 1996 Altman DG, Bland JM. Detecting skewness from summary information. BMJ 1996;313(7066):1200.
2. Alwahabbi 2003 Alwahabbi F. Anxiety symptoms and generalized anxiety disorder in the elderly: a review. Harvard Review of Psychiatry 2003;11(4):180-93.
3. APA 1980 American Psychiatric Association. Diagnostic and statisticalmanual of mental disorrders -DSM-III. 3rd Edition. Washington, DC:American Psychiatric Association, 1980.
4. APA 1987 American Psychiatric Association. Diagnostic and statisticalmanual of mental disorders - DSM-III-R. 3rd Edition. Washington, DC: American Psychiatric Association, 1987.
5. APA 1994 American Psychiatric Association. Diagnostic and statisrtical manual of mental disorders - DSM-IV. 4th Edition. Washington, DC: American Psychiatric Association, 1994.
6. Baldwin 2005 Baldwin DS, Montgomery SA, Nil R, Lader M. Discontinuation symptoms in depression and anxiety disorders. International Journal of Neuropsychopharmacology 2005;19:1-12.
7. Barranco 1977 Barranco SF. Treatment of anxiety with oral hydroxyzine: an overview. Current Therapeutic Research 1977;22:217-27.
8. Barrett 1988 Barrett JE, Barrett JA, Oxman TE, Gerber PD. The prevalence of psychiatric disorders in a primary care practice. Archives of General Psychiatry 1988;45:1100-6.
9. Brawman-Mintzer 1993 Brawman-Mintzer O, Lydiard RB, Emmanuel N, Payeur R, Johnson M, Roberts J, et al.Psychiatric comorbidity in patients with generalized anxiety disorders. American Journal of Psychiatry 1993;150:1216-8.
10. Caycedo 2001 Caycedo N, Griez EJ. Generalised anxiety disorder. In: Griez EJL, Faravelli C, Nutt D, Zohar J editor(s). Anxiety Disorders. Chichester: Wiley, 2001:187-204.
11. Chessick 2006 Chessick CA, Allen MH, Thase M, Batista Miralha da Cunha AB, Kapczinski FF, de Lima MS, et al.Azapirones for generalized anxiety disorder. Cochrane Database of Systematic Reviews 2006, Issue 3.Art. No.: CD006115. DOI:10.1002/14651858.CD006115.
12. Ferreri 1998 Ferreri M, Hantouche EG. Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatrica Scandinavica, Supplementum 1998;393:102-8.
13. Furukawa 2002 Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31:76-7.
14. Furukawa 2005 Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in metaanalyses. International Clinical Pscyhopharmacology 2005;20:49-52.
15. Furukawa 2006 Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2006;59:7-10.
16. Guy 1976 Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare publication. 2. Rockville, MD: National Institute of Mental Health, 1976:218-22.
17. Hamilton 1959 Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;31:50-5.
18. Higgins 2006 Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]. Vol. 4, The Cochrane Library, Chichester, UK: John Wiley & Sons, Ltd, 2006.
19. Kapczinski 2003 Kapczinski F, Lima MS, Souza JS, Schmitt R. Antidepressants for generalized anxiety disorder. Cochrane Database of Systematic Reviews 2003, Issue 2.Art. No.: CD003592. DOI:10.1002/14651858. CD003592.
20. Kessler 1998 Kessler RC, Stang PE, Wittchen HU, Ustun TB, Roy-Burne PP, Walters EE. Lifetime depression comorbidity in the National Comorbidity Survey. Archvies of General Psychiatry 1998;55:801-8.
21. Oxman 1992 Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Annals of Internal Medicine 1992;116:78-84.
22. Papadopoulous 1990 Papadopoulous CL. Anxiolysis as a modifying factor of certain neuropsychiatric parameters in patients with coronary heart diseases. Neurologie Psychiatrie 1990;April:7-8.
23. Rickels 1993 Rickels K, Downing G, Schweizer E, Hassman H. Antidepressants for the treatment of generalised amxiety disorder: a placebo-controlled comparison of imipramine, trazodone and diazepam. Archives of General Psychiatry 1993;50:884-95.
24. Schmitt 2005 Schmitt R, Gazalle FK, Silva de Lima M, Cunha A, Souza J, Kapczinski F. The efficacy of antidepressants for generalized anxiety disorder: a systematic review andmeta-analysis. Revista Brasileria de Psiquiatria 2005;27:18-24.
25. Shalowitz 1961 Shalowitz MJ. Evaluation of an ataraxic (hydroxyzine) in long-term therapy. International Records in Medicine 1961;174:367-71.
26. Shiloh 2006 Shiolh R, Stryjer R, Weizman A, Butt D. Atlas of Psychiatric Pharmacotherapy. 2nd Edition. London: Taylor & Francis, 2006.
27. Stahl 2000 Stahl S. Essentials of Psychopharmacology. Cambridge: Cambdridge University Press, 2000.
28. Warner 2006 Warner CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. American Family Physician 2006;74:449-56.
29. WHO 1978 World Health Organization. The Ninth Revision of the International Classification of Diseases and Related Health Problems (ICD-9). Geneva: World Health Organization, 1978.
30. WHO 1992 World Health Organization. The Tenth Revision of the International Classification of Diseases and Related Health Problems (ICD-10). Geneva: World Health Organization, 1992.
31. Wittchen 1994 Wittchen HU, Zhao S, Kessler RC, Eaton WW. DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Archives of General Psychiatry 1994;51:355-64.